Cervical cancer最新文献

{"title":"2022-RA-1415-ESGO Perspective on the future of the sentinel lymph node in cervical cancer","authors":"A. Manu, Diana-Elena Soare, Alexandra Irma Gabriela Bausic, C. Coroleucă, E. Brătilă","doi":"10.1136/ijgc-2022-esgo.126","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.126","url":null,"abstract":"with recurrent/metastatic cervical cancer (r/mCC). Previous reports show potentially enhanced efficacy and tolerable safety with TV + pembrolizumab, carboplatin, or bevacizumab. We report interim safety and efficacy results from the dose-expansion cohorts evaluating 1L TV + pembrolizumab (1L-TP), 2/ 3L TV + pembrolizumab (2/3L-TP), and 1L TV + carboplatin (1L-TC) in patients with r/mCC. Methodology In the 1L-TP cohort, patients with r/mCC who had no prior systemic therapy (excluding chemoradiation) received TV 2.0 mg/kg + pembrolizumab 200 mg IV Q3W. In the 2/3L-TP cohort, patients with r/mCC who experienced disease progression on/after 1–2 prior systemic therapies received TV 2.0 mg/kg + pembrolizumab 200 mg IV Q3W. In the 1L-TC cohort, patients with r/mCC who had no prior systemic therapy (excluding chemoradiation) received TV 2.0 mg/kg + carboplatin AUC 5 IV Q3W. The primary end point was confirmed objective response rate (cORR) per RECIST v1.1. Results In the 1L-TP, 2/3L-TP, and 1L-TC cohorts, respectively, 33, 35, and 33 patients received treatment, and, at data cutoff, median follow-up was 18.8, 15.0, and 14.6 months. cORR was 41%, 38%, and 55%, with a median DOR of not reached, 14.0, and 8.6 months in the 1L-TP, 2/3L-TP, and 1LTC cohorts, respectively. Adverse events (AEs) of special interest in patients in the 1L-TP, 2/3L-TP, and 1L-TC cohorts (grade 1–2/grade 3) included ocular events (58/9; 51/3; 58/ 9), bleeding (61/6; 61/9; 52/6), and peripheral neuropathy (49/3; 37/3; 48/12), respectively; one patient in 2/3L-TP and one patient in 1L-TP experienced grade 4 and 5 treatmentrelated bleeding, respectively. Additional data will be presented at the meeting. Conclusion TV + pembrolizumab or carboplatin in patients with r/mCC demonstrated encouraging and durable antitumour activity, with tolerable safety profiles. © 2022 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Annual Meeting. All rights reserved.","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115704100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-908-ESGO The importance of pathological ultrastaging for sentinel lymph nodebiopsy in cervical cancer, the final outcome of the Sentix study (CEEGOG-CX01; ENGOT-CX2; NCT02494063)","authors":"R. Kocián, C. Koehler, S. Bajsova, J. Jarkovský, I. Zapardiel, G. Martino, L. V. van Lonkhuijzen, B. Sehnal, O. A. Sánchez, Blanca Gil- Ibañez, F. Martinelli, Jiri Presl, L. Minář, R. Marek, P. Kascak, P. Havelka, M. Michal, T. Van Gorp, K. Němejcová, D. Cibula","doi":"10.1136/ijgc-2022-esgo.69","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.69","url":null,"abstract":"2022-RA-908-ESGO Figure 1 Conclusion Pathological ultrastaging is a key component of the SLN concept in cervical cancer. It enables detection of additional 44% of patients with N1 (MAC, MIC) and almost all (91%) with ITC. The detection of positive SLN directly correlates with the intensity of ultrastaging. Four levels should become an international standard, which allows to detect over 90% of N1 (MAC, MIC). 2022-VA-920-ESGO ADRENAL GLAND RECURRENT CERVICAL CANCER TREATED BY MINIMALLY INVASIVE APPROACH Andrea Rosati, Camilla Certelli, Giulia Scaglione, Alessandro Baroni, Alex Federico, Filippo Maria Capomacchia, Pierfrancesco Greco, Francesco Fanfani, Giovanni Scambia, Valerio Gallotta. Policlinico Agostino Gemelli, Roma, Italy 10.1136/ijgc-2022-ESGO.70 Introduction/Background Recurrence of disease represents a clinical challenge in cervical cancer patients and the choice of the best treatment depends on previous therapy and site of recurrent tumor. The paraortic lymph nodes and the lungs were the extrapelvic areas more frequently involved, whereas adrenal gland involvement is rarely reported. Some reports confirmed the survival benefit of secondary radical surgery in confined recurrence, although this finding has been rarely investigated in the literature with only a few case series reported mostly focusing on lung metastases. Methodology Here a case of isolated adrenal gland cervical cancer recurrence in a 62-year-old woman is presented. Preoperative computed and emission tomography scans detected a nodule of 26 mm with increased uptake involving the medial lip of the right adrenal gland and a lymph node of 8 mm behind the inferior vena cava. A retrocaval lymphadenectomy and right adrenalectomy was performed. In this video we showed a minimally invasive approach tailored on the patient disease with the help of intraoperative ultrasound. Results We reached a residual tumor of zero with good operation times. No intra or postoperative complications occurred. Final histology confirmed the metastatic involvement of both the adrenal gland and the retrocaval lymph node by an undifferentiated carcinoma. After a multidisciplinary board evaluation, the patient underwent chemotherapy. Conclusion Minimally invasive surgery in selected patients with isolated extrapelvic cervical cancer recurrence is feasible and safe. Since radicality may be guaranteed by intraoperative imaging such as ultrasound, surgery can be tailored on the single patient and disease. 2022-RA-926-ESGO AWARENESS, ATTITUDES AND PRACTICES OF WOMEN IN RELATION TO CERVICAL CANCER SCREENING IN MAINLAND CHINA Sumeng Wang, Youlin Qiao. Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Center for Global Health, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China ","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124557930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-755-ESGO Comparison of PD-L1 status between primary and paired recurrent/metastatic cervical cancer","authors":"B. Ataseven, T. Dagres, F. Heitz, N. Concin, T. Thomas, M. Imterat, N. Pauly, S. Heikaus, A. Traut, M. Moubarak, P. Harter","doi":"10.1136/ijgc-2022-esgo.56","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.56","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115100418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1625-ESGO Diagnostic performance of PAP-smear and HPV-testing in the follow-up of patients with cervical cancer","authors":"Andres Rave Ramirez, O. A. Sánchez, L. Sala, D. G. Garcia-Cano, Alicia Martín Martínez, Beatriz Navarro","doi":"10.1136/ijgc-2022-esgo.147","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.147","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"114 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124122531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1259-ESGO Brachytherapy and surgery versus surgery alone for IB2 (FIGO 2018) cervical cancers: A FRANCOGYN study","authors":"Othman Aissaoui, Jérôme Phalipou, A. Cordoba, H. Azais, L. Ouldamer, P. Bolze, M. Ballester, C. Huchon, C. Mimoun, C. Akladios, L. Lecointre, E. Raimond, O. Graesslin, X. Carcopino, V. Lavoué, S. Bendifallah, C. Touboul, Y. Dabi, G. Canlorbe, M. Koskas, P. Chauvet, P. Collinet, Y. Kerbage","doi":"10.1136/ijgc-2022-esgo.110","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.110","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128746728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1244-ESGO Surgical paraaortic lymph node staging does not delay concomitant chemoradiation starting and completion in locally advanced cervical compared with FDG-TEP staging. A retrospective single-center cohort","authors":"D. Hudry, E. Bogart, M. Benna, Camille Pasquesoone, H. E. Hajj, H. Gauthier, S. Taieb, S. Bécourt, Mathilde Duchatelet, F. Tinier, Abesse Ahmeidi, É. Leblanc, M. Deley, F. Narducci, Carlos Martinez Gomez, A. Cordoba","doi":"10.1136/ijgc-2022-esgo.105","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.105","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130741382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-678-ESGO CONTESSA/NEOCON-F trial: Assessing the effectiveness and safety of neoadjuvant chemotherapy followed by fertility-sparing surgery in FIGO 2018 stage IB2 cervical cancer","authors":"M. Plante, N. V. van Trommel, Mirte Schaafsma, A. Oza, Angela Rodriguez, Lisa Wang, K. Sikorska, S. Ferguson, K. Han, S. Lheureux, F. Amant","doi":"10.1136/ijgc-2022-esgo.45","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.45","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130982281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-181-ESGO Updated systematic review about results of fertility sparing surgery of cervical cancer","authors":"S. Gouy, S. Schérier, A. Maulard, F. Zaccarini, J. Zarokian, C. Sanson, S. Espenel, A. Leary, P. Pautier, C. Genestie, C. Chargari, M. Grynberg, P. Morice","doi":"10.1136/ijgc-2022-esgo.6","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.6","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126835941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-971-ESGO Laparotomy spared rate in two steps surgery for early stage cervical cancer","authors":"Blanca Segarra Vidal, Pedro M Beira. Salvador, Víctor Lago Leal, P. Iserte, S. D. D. Pozo","doi":"10.1136/ijgc-2022-esgo.77","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.77","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121471752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-452-ESGO Automatic semantic segmentation of cervical cancer based on dynamic contrast-enhanced MRI and fully convolutional networks","authors":"Shaojun Xia, Hai-Tao Zhu, Bo Zhao, Kun Cao, Xiao-ting Li, Yingshi Sun","doi":"10.1136/ijgc-2022-esgo.28","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.28","url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"291 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122979606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}